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Effects of adenosine A1 receptor agonist CCPA and antagonist
DPCPX on ischemia/reperfusion-induced arrhythmias in rats*
Ömer BOZDOĞAN1, Ersöz GONCA2, Nuran EKERBİÇER3
Aim: Adenosine has been commonly used to treat supraventricular tachycardia in clinics. However, there are only a few
studies on the effects of adenosine on ischemia or reperfusion induced arrhythmia and they conflict with the results of
the present study. During this study, we aimed to clarify the effect of adenosine on ischemia-reperfusion induced
arrhythmia.
Materials and methods: Left coronary artery was ligated for 6 min and it was released for 15 min to produce reperfusion.
A1 adenosine agonist CCPA (2 Chloro - N6 – Cyclopentyl-adenosine), and A1 selective antagonist DPCPX (8 –
Cyclopentyl - 1,3 -dipropylxanthine) in 5 μg/kg dose alone and in combination were given intravenously before ligation,
at the second minute of the ligation and just following the reperfusion.
Results: Adenosine given only at the second minute of the ligation is found to decrease the total duration of arrhythmia
observed in the reperfusion stage. DPCPX given in this period is found to block the antiarrhythmic effect of adenosine.
Adenosine given after reperfusion and before ligation was not effective in decreasing reperfusion induced arrhythmia.
Conclusion: The time dependent effect of the administration during ischemia and reperfusion was important for the
effect of adenosine. The present study showed that antiarrhythmia produced by adenosine is related to the activation of
A1 adenosine receptor.
Key words: Ischemia, reperfusion, arrhythmias, adenosine

Sıçanlarda, adenozin agonisti, CCPA, ve antagonisti DPCPX’in iskemi / reperfüzyon
ile uyarılan aritmiler üzerine etkisi
Amaç: Adenozin supraventriküler taşikardili hastaların tedavisinde kullanılan etkili bir ilaçtır. Ancak, adenozinin iskemi
ve reperfüzyon aritmileri üzerine adsenozin etkisi ile ilgili sadece bir kaç çalışma vardır ve bunlarında sonuçları
tartışmalıdır. Bu çalışmada adenozinin iskemi-reperfüzyon aritmileri üzerine etkisinin araştırılması amaçlanmıştır.
Yöntem ve gereç: Sol koroner arter bağlanarak 6 dakika iskemi ve bağ gevşetilerek 15 dakika reperfüzyon yapılmıştır. Bir
A1 adenozin reseptor agonisti olan CCPA (2 Chloro - N6 – Cyclopentyl-adenosine) ve anatgonisti, DPCPX (8Cyclopentyl-1,3-dipropylxanthine), 5 μg/kg dozunda tek ve birlikte iskemiden önce, iskeminin ikinci dakikasında ve
reperfüzyonu hemen takiben intravenöz olarak verilmiştir.
Bulgular: Sadece ligasyonun ikinci dakikasında verilen CCPA, 15 dakikalık reperfüzyon boyunca oluşan aritmi süresini
azaltmıştır. Bu dönemde verilen adenozin antagonisti, DPCPX, adenozinin bu antiaritmik etkisini ortadan kaldırmıştır.
Reperfüzyon sırasında ve ligasyondan önce verilen adenozinin reperfüzyonu takiben oluşan aritmiler üzerine bir etkisi
olmamıştır.
Sonuç: İskemi ve reperfüzyon sırasında veriliş zamanı, adenozinin etkisinde önemlidir. Bu çalışma adenozin ile
oluşturulan antiaritminin, A1 adenozin reseptorlarının aktivasyonu ile ilgili olduğunu göstermiştir.
Anahtar sözcükler: İskemi, reperfüzyon, aritmiler, adenozin
Received: 08,06.2008 – Accepted: 20.08.2009
1
Department of Biology, Faculty of Arts and Sciences, Abant İzzet Baysal University, 14280 Bolu - TURKEY
2
Department of Biology, Faculty of Arts and Sciences, Zonguldak Kara Elmas University, Merkez Zonguldak - TURKEY
3
Department of Physiology Faculty of Medicine, Celal Bayar University, Muğla - TURKEY
Correspondence: Ömer BOZDOĞAN, Department of Biology, Faculty of Arts and Sciences, Abant İzzet Baysal University, 14280 Bolu - TURKEY
E-mail: bozdogan_o@ibu.edu.tr
* This study was performed in the Biology Department of the Faculty of Art and Science, Abant İzzet Baysal University, Bolu-Turkey, and supported by a research fund
from Abant İzzet Baysal University (03.08.02.182).

249

Effect of adenosine A1 receptor agonist

Introduction
Adenosine is currently used as an antiarrhythmic
agent in infants and children (1). It may exert its
action either by both direct effect on potassium
conductance and indirect antiadrenergic action (2) or
depressing sinoatrial node activity and attenuating
atrioventricular nodal conduction (3).
Extracellular levels of adenosine increase under
various conditions, such as ischemia, trauma, seizures
and inflammation, due to energy demands and ATP
metabolism (4). It is known that the concentration of
adenosine in the coronary effluent markedly increases
following ischemia (5). In most of the experimental
models, adenosine receptor stimulation triggers
preconditioning against myocardial ischemia in rats (57). On the other hand, there are also some studies
indicating no preconditioning effect of adenosine
against arrhythmia and infarct size (8-10). It has been
shown that adenosine reduces infarct size but does not
affect the incidence and severity of arrhythmias
following ischemia (11). In another study, it has been
observed that adenosine given prior to coronary
occlusion reduced the ventricular arrhythmias (12).
Similarly, this effect was seen when adenosine was
given by infusion into the left ventricle (13). Several
studies have demonstrated that adenosine reduced the
incidence of arrhythmias in the isolated perfused rat
heart as well as anesthetized rats subjected to acute
myocardial ischemia (14). In a recent study, it has been
shown that adenosine A1 receptor agonist (CCPA)
alone did not decrease the duration of arrhythmia
during ischemia and even induced lethal arrhythmia
during reperfusion (15). However, when it is given
together with lidocain, it decreases the arrhythmia. The
antiarrhythmic effect of adenosine and its agonist in
myocardial ischemia and reperfusion is still unclear.
The present study aimed to contribute to the debate by
investigating the effect of adenosine on the
arrhythmias in ischemia and reperfusion.
Materials and methods
Eighty-seven 7- to 8-month-old male Sprague
Dawley rats weighing 250-325g were used. The animals
were fed a standard laboratory rat food pellet and
allowed to drink tap water ad libitum. All animals were
treated in adherence to all of the guiding principles in
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the care and use of animals together with the
recommendation from the Declaration of Helsinki.
Rats were anesthetized with thiopental sodium
(100 mg/kg) and tracheotomy was performed for
artificial respiration. The left carotid artery was
cannulated to measure blood pressure with a blood
pressure transducer (Biopac System Inc, Goleta, CA,
USA, under the authorized distribution of the
representative Commat-Ankara/Turkey). After the
chest was opened in the fourth intercostal space, the
heart was exposed and a loose loop of traumatic silk
was placed around the left main coronary artery,
approximately 2 mm from its origin. The heart was
returned to its place and artificial respiration was
performed using a ventilator (0.9 mL/100 g body
weight at a rate of 60 strokes/min). The animals were
allowed to stabilize for 5 min before coronary ligation.
The 6 min of ischemia was followed by 15 min of
reperfusion. In this technique, ligation was achieved
by tightening the silk by producing a bowknot and
reperfusion was produced by pulling the silk through
the bowknot.
At the end of the experiment, the live animals were
heparinized (500 IU/kg) and the heart was excised
out. The left coronary artery was retightened and
coronaries were perfused with 10 mL of isotonic NaCl
solution and then 2 mL of ethanol for demarcation of
the occluded and non-occluded myocardium. The
occluded myocardium and nonoccluded myocardium
were separated from each other by dissection and
then both areas were weighed individually. The
percentage of ventricular myocardium under the risk
of infarction was determined.
The experiment was designed in 4 main groups: 1
control and 3 drug-treated groups, including CCPA,
DPCPX, and CCPA + DPCPX. In the control group,
there was no drug treatment; only coronary ligation
was performed. Each drug treated group was divided
into 3 subgroups as drug given 10 min before ligation,
at the 2nd minute of ligation, and following
reperfusion. A1 Adenosine receptor agonist (2 Chloro
- N6 – Cyclopentyl-adenosine, CCPA), A1 adenosine
blocker
(8-Cyclopentyl-1,3-dipropylxanthine,
DPCPX), obtained from Sigma Chemical Co. Inc., St.
Louis, Missouri, USA, under the authorized
distribution of the representative Interlab-İstanbul,
Turkey, were prepared in physiological saline and
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given intravenously in a dose of 5 μg/kg per 100 μL, 10
min before ligation, at the 2nd minute of ligation, and
just following reperfusion from tail veins. Adenosine
blocker was prepared and given alone or in
combination with adenosine in the same dose and
protocol similar to adenosine. The dose of adenosine
A1 receptor agonist was determined by the
preliminary studies in the literature according to its
effect on the heart rate. A dose larger than 5 μg/kg
caused severe bradycardia and cardiac arrest. All
drugs were prepared daily before injection.
Bipolar ECG was recorded using needle
electrodes, and blood pressure was measured from the
carotid artery by a blood pressure transducer and
stored on a computer using the Biopac System. The
duration of the arrhythmia and the heart rate were
determined from the ECG using BSL Pro 3.7 software
of Biopac. The incidence of arrhythmias was analyzed
in accordance with the Lambeth Conventions (16), as
ventricular fibrillation (VF), ventricular tachycardia
(VT), and other types of arrhythmias including
extrasystoles, bigeminy, and salvos (VPC). An
arrhythmia score was used to indicate the incidence
and the duration of arrhythmias, where 0 indicates no
arrhythmia, 1 indicates an arrhythmia duration of less
than 10 s, 2 indicates an arrhythmia duration of 11 to
30 s, 3 indicates an arrhythmia duration of 91 to 180
s or reversible VF for less than 10 s, 5 indicates
arrhythmia duration longer than 180 s or reversible
VF for more than 10 s, and 6 indicates irreversible VF
or death of the animal.
All data are expressed as mean ± standard error.
Differences between groups were calculated using
analyses of variance. After analyses of variance (LSD
post hoc test), the test groups and the control group
were compared by Student’s t-test (unpaired). The
survival rate and the incidence of arrhythmias were
2
compared by the X method (Fisher’s exact test).
Results
ST segment elevation and an increase in QRS
amplitude and the heart rate were observed following
the coronary artery ligation in all animals. The
animals having low blood pressure below 70 mmHg
before ligation (one animal) were excluded from the
experiment. Three animals in a group that CCPA and

an animal that CCPA and DPCPX were given before
ligation, in addition to the 4 animals that were
supplied with adenosine during ligation died due to
severe bradycardia and cardiac arrest associated with
low blood pressure below 20 mmHg. There were no
significant differences in the risk of infarct area
among the groups and the data are not shown.
Blood pressure and heart rate decreased
significantly according to the control in the
reperfusion period of the drug treated group that was
given CCPA before ligation (Tables 1 and 2) (P <
0.05). A similar effect of CCPA was not seen when it
was given in combination with adenosine A1 selective
blocker DPCPX. On the other hand, DPCPX, which
was given at the 2nd minute of ligation alone,
decreased the blood pressure and it was not effective
on the blood pressure in other groups that were given
DPCPX before ligation or during reperfusion.
DPCPX and CCPA alone, which were given at the 2nd
minute of ligation, did not produce any appreciable
effect on the blood pressure recorded in the coronary
ligation and reperfusion period according to the
control as shown in Table 1. The heart rate in the
reperfusion period of animals given CCPA at the 2nd
minute of ligation was significantly lower than that of
the control animals (P < 0.01). This decline in the
heart rate stopped when the CCPA was given in
combination with DPCPX (Table 2).
The arrhythmic period, which was between the
start and the end of the arrhythmia in the 15th minute
of reperfusion, was not significantly different in the
drug treated groups when compared with the control
group. CCPA that was given at the 2nd minute of the
ligation decreased the score of arrhythmia
significantly (P < 0.05); it was 1.6 ± 0.56 in the CCPA
group and 3.5 ± 0.26 in the control group (Table 3).
The duration of ventricular tachycardia (12 ± 6 s in
CCPA, 48 ± 10 s in the control group) (Figure 1) and
the total arrhythmia (33 ± 14 s in CCPA, 101 ± 50 s in
the control group) during reperfusion (Figure 2) were
also lower in that group of animals compared with the
control group (P < 0.05). The combination of CCPA
with DPCPX prevented this antiarrhythmic effect of
CCPA. There was no observable individual effect of
DPCPX on the reperfusion induced arrhythmia given
before the ligation, at the 2nd minute of ligation, and
during reperfusion.
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Table 1. Mean arterial blood pressure in anesthetized rats. Mean ± standard error. *P < 0.05, **P < 0.01; Difference from control.
Blood Pressure, mmHg
Group

N

Before
Occlusion

Following Occlusion

Following Reperfusion

1 min

3 min

5 min

1 min

3 min

5 min

10 min

15 min

Control

8

114 ± 8

84 ± 8

84 ± 11

84 ± 12

90 ± 7

93 ± 11

104 ± 9

117 ± 8

118 ± 9

A1 Adenosine Receptor Agonist,
CCPA (Before ligation)
A1 Adenosine Receptor Agonist,
CCPA (At 2 min of ligation)
A1 Adenosine Receptor Agonist,
CCPA (Following reperfusion)
A1 Adenosine Blocker,
DPCPX (Before ligation)
A1 Adenosine Blocker,
DPCPX (At 2 min of ligation)
A1 Adenosine Blocker,
DPCPX (Following reperfusion)
CCPA + DPCPX
(Before ligation)
CCPA + DPCPX
(At 2 min of ligation)
CCPA + DPCPX
(Following reperfusion)

9

114 ± 8

63 ± 9

58 ± 10

62 ± 11

56 ± 10*

75 ± 12

70 ± 13*

78 ± 13**

104 ± 9

8

112 ± 5

89 ± 11

89 ± 14

87 ± 13

73 ± 10

88 ± 12

103 ± 7

98 ± 7

97 ± 8

8

126 ± 8

89 ± 12

101 ± 12

92 ± 15

79 ± 13

91 ± 16

102 ± 9

102 ± 6

110 ± 8

6

120 ± 11

91 ± 12

94 ± 13

95 ± 14

71 ± 16

93 ± 12

101 ± 11

110 ± 6

110 ± 5

8

128 ± 7

92 ± 8

93 ± 11

83 ± 13

72 ± 11

74 ± 13

73 ± 16

84 ± 11*

82 ± 12*

6

121 ± 5

89 ± 11

89 ± 14

80 ± 17

74 ± 14

81 ± 16

82 ± 13

100 ± 7

103 ± 7

6

118 ± 4

71 ± 8

71 ± 16

70 ± 16

98 ± 11

102 ± 8

99 ± 10

102 ± 10

97 ± 12

6

125 ± 2

94 ± 11

86 ± 19

88 ± 11

64 ± 11

74 ± 12

77 ± 11

90 ± 11*

91 ± 11*

6

114 ± 8

89 ± 11

96 ± 11

98 ± 12

100 ± 14

117 ± 4

122 ± 3

121 ± 7

122 ± 7

Table 2. Heart rate in anesthetized rats. Mean ± standard error *P < 0.05, **P < 0.01; Difference from control.
Heart Rate Beats /Min
Group

N

Before
Occlusion

Following Occlusion

Following Reperfusion

1 min

3 min

5 min

1 min

3 min

5 min

10 min

15 min

395 ± 24

398 ± 23

372 ± 31

414 ± 33

388 ± 23

400 ± 24 405 ± 24
326 ± 9* 345 ± 11*

Control

8

403 ± 6

399 ± 25

A1 Adenosine Receptor Agonist,
CCPA (Before ligation)
A1 Adenosine Receptor Agonist,
CCPA (At 2 min of ligation)
A1 Adenosine Receptor Agonist,
CCPA (Following reperfusion)
A1 Adenosine Blocker,
DPCPX (Before ligation)
A1 Adenosine Blocker,
DPCPX (At 2 min of ligation)
A1 Adenosine Blocker,
DPCPX (Following reperfusion)
CCPA + DPCPX
(Before ligation)
CCPA + DPCPX
(At 2 min of ligation)
CCPA + DPCPX
(Following reperfusion)

9

366 ± 5

306 ± 1** 302 ± 21** 282 ± 20** 295 ± 34

329 ± 13* 321 ± 12*

8

387 ± 9

376 ± 15

342 ± 32

330 ± 32

336 ± 38

289 ± 27** 302 ± 22* 312 ± 21** 310 ± 23**

8

418 ± 4

444 ± 15* 395 ± 30

400 ± 34

384 ± 49

363 ± 31

339 ± 30

387 ± 43 340 ± 24*

6

442 ± 7

418 ± 13

424 ± 8

420 ± 5

330 ± 35

367 ± 13

380 ± 17

377 ± 18 394 ± 16

6

440 ± 10

436 ± 12

425 ± 12

428 ± 14

360 ± 40

348 ± 38

334 ± 40

347 ± 27 357 ± 19

6

436 ± 5

424 ± 18

423 ± 21

426 ± 22

323 ± 41

335 ± 37* 362 ± 36 317 ± 18* 343 ± 22*

6

382 ± 8

364 ± 13

349 ± 15

362 ± 20

436 ± 13

432 ± 17

434 ± 11

436 ± 15 432 ± 12

8

420 ± 7

428 ± 14

375 ± 49

365 ± 46

445 ± 26

416 ± 17

404 ± 18

409 ± 13 405 ± 15

6

379 ± 10

377 ± 14

388 ± 12

396 ± 17

411 ± 7

389 ± 15

406 ± 11

410 ± 11
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Table 3. The incidence and score of arrhythmia after 15 min of reperfusion (mean ± standard error) *P < 0.05, Difference from control.
Group

N

No arrhythmia
N/%

Death during
reperfusion
N/%

Incidence of arrhythmia, n / %
VPC

VT

VF

Br

Score
of
arrhythmia

Control

8

0/0

0/0

8 / 100

8 /100

0/0

0/0

3.5 ± 0.26

A1 Adenosine Receptor Agonist,
CCPA (before ligation)

10

0/0

1 / 10

10 / 100

8 / 80

3 / 30

3 / 30

3.6 ± 0.45

A1 Adenosine Receptor Agonist,
CCPA (At 2 min of ligation)

8

3 / 37

0/0

5 / 62

5 / 62

0/0

3 / 37

1.6 ± 0.56*

A1 Adenosine Receptor Agonist,
CCPA (Following reperfusion)

9

0/0

1 / 11

9 / 100

8 / 89

2 / 22

2 / 22

3.3 ± 0.5

A1 Adenosine Blocker,
DPCPX (Before ligation)

7

0/0

1 / 14

7 /100

6 / 86

1 / 14

0/0

3.1 ± 0.63

A1 Adenosine Blocker,
DPCPX (At 2 min of ligation)

8

1 / 12

0/0

7 / 87

7 / 87

1 / 12

0/0

2.8 ± 0.47

A1 Adenosine Blocker,
DPCPX (Following reperfusion)

8

0/0

2 / 25

8 /100

7 / 87

0/0

0/0

3.8 ± 1.8

CCPA + DPCPX
(Before ligation)

6

0/0

0/0

6 / 100

5 / 83

0/0

2 / 33

3.0 ± 0.44

CCPA + DPCPX
(At 2 min of ligation)

6

2 / 33

0/0

4 / 67

4 / 67

0/0

0/0

2.1 ± 0.7

ACCPA + DPCPX
(Following reperfusion)

8

0/0

2 / 25

6 / 75

4 / 50

0/0

0/0

3.7 ± 1.7

70

60

Second

50

40

30

20

*

10

0

Control

CCPA Before
ligation

CCPA
At 2 min of
ligation

CCPA
Following
Reperfusion

DPCPX
Before
ligation

DPCPX
At 2 min of
ligation

CCPA+DPCPX CCPA+DPCPX CCPA+DPCPX
DPCPX
Before
At 2 min
Following
Following
ligation
of ligation
reperfusion
reperfusion

Figure 1. Duration of ventricular tachycardia observed during 15 min of reperfusion P < 0.05.
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CCPA+DPCPX Following ligation
CCPA+DPCPX At 2 min ligation

VPC
VT

CCPA+DPCPX Before ligation

VF
DPCPX Following ligation
DPCPX At 2 min of ligation
DPCPX Before ligation
CCPA Following ligation
CCPA At 2 min of ligation

*

CCPA Before ligation
Control
0

20

40

60
Second

80

100

120

Figure 2. The type and duration of arrhythmias during 15 min of reperfusion P < 0.05; difference of total arrhythmia from control.

The incidence of arrhythmia in the 15th minute of
reperfusion changed with the treatment of CCPA or
DPCPX alone or in combination (Table 3). The risk
of an infarct zone in the drug treated groups did not
change with respect to the control group and it was
above 40% in all groups of animals.
Discussion
The important findings of the present study can be
summarized as follows: adenosine A1 receptor agonist
CCPA is effective in decreasing arrhythmias induced
by reperfusion. The timing of the administration of
CCPA is found to be crucially important in decreasing
the arrhythmia. Adenosine A1 receptor antagonist
DPCPX was found to block the antiarrhythmic effect
of CCPA, indicating that adenosine’s effectiveness
depends on the stimulation of the A1 receptors.
Among these findings, the time dependence of the
effect is the most important and the novel
observation. No comparable study that focused on the
time dependent effect of adenosine was found in the
literature using an experimental protocol similar to
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the one in the present study. Although the time
dependence cannot be explained by the results of the
present study, we can make some suggestions about
its mechanism. It is well known that endogenous
adenosine is released during the ischemic period.
Since the adenosine molecule has a short lifespan, the
decrease in the endogenous adenosine is replenished
by the exogenous adenosine and the level of
adenosine is maintained. Larger doses given before or
during ligation lead to death of animals due to cardiac
arrest. That is why CCPA given during ligation in a
dose of 5 μg/kg may be effective in decreasing
reperfusion induced arrhythmia. It may also be
suggested that the effectiveness of adenosine A1
receptor agonist to decrease reperfusion induced
arrhythmia given during ligation period may be
related to the fact that adenosine might have effects
also on non-myocardial cells. In the reperfusion
process there might be no endogenous release of
adenosine and exogenous adenosine is found to be
non-effective, probably due to the below threshold
amount. The exact mechanism for the importance of
the time dependent effect of adenosine needs further
study.
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In the present study, adenosine A1 receptor
agonist decreased the blood pressure and induced
bradycardia; similar results were already observed by
Shen et al. and Belloni et al. (17,18). CCPA given at
the 2nd minute of ligation decreased the duration of
the total arrhythmia and ventricular tachycardia with
respect to the control animals. Blockage of adenosine
A1 receptor prevented this protective effect.
We found that adenosine CCPA was effective in
decreasing arrhythmias induced by reperfusion.
Canyon et al. (15) reported that adenosine A1 agonist
given at the ligation period by infusion did not
decrease arrhythmia in reperfusion. However, when
it was given in combination with lidocain, it was
found to be effective in decreasing the ventricular
arrhythmia. Wainright and Parratt (12) found that
pretreatment of adenosine A1 agonist R-PIA before
ligation decreased ischemia induced arrhythmia. The
left ventricular infusion of adenosine reduced the
incidence of ventricular fibrillation (13).
Although selective adenosine A1 receptor blocker
DPCPX alone did not affect ischemia or reperfusion
induced arrhythmia, it was found to suppress the
antiarrhythmic effect produced by CCPA applied
during the ligation period. The underlying
mechanism in the antiarrhythmic effect of adenosine,
especially given during the ligation period, was the
subject of many studies. These studies pointed to the
important relation between the adenosine A1 receptor
activation and the regulation of K (ATP) channel
opening (19,20). The antiarrhythmic effect produced
by adenosine is similar to the effect of ATP dependent
potassium channel opener (17). Both agents have

antiadrenergic effects and cause bradycardia and even
cardiac arrest (21). Some researchers suggest that
openers decrease infarct size and arrhythmia (20,22),
but others report opposite results (23,24). The same
is true for ATP dependent potassium channel blocker
(25,26). If the adenosine A1 receptor activation leads
to the opening of the K (ATP) channel, blockage of
the adenosine A1 receptor could be expected to keep
the channel closed. In the present study, blockage of
adenosine A1 receptor was found not to increase the
reperfusion induced arrhythmia, but it reversed the
antiarrhythmic effect of adenosine. Lee et al. (27)
showed that DPCPX enhanced arrhythmia but
adenosine A1 receptor agonist BN-063 given before
ligation decreased arrhythmia after 30 min of
coronary ligation. The effectiveness of DPCPX in that
study may depend on a higher dose of DPCPX.
During the present study DPCPX was used in a dose
of 5 μg/kg, but previously Lee et al. (27) used DPCPX
in a 0.5 mg/kg dose.
In summary of the findings of the present study,
the effect of adenosine agonist CCPA on the
ischemia/reperfusion induced arrhythmia depends on
the time and dose of its administration. Adenosine
agonist given in a bolus injection just following
coronary ligation in rats is effective in decreasing
reperfusion induced arrhythmia.
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